A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Crizotinib (Primary) ; Dasatinib (Primary)
- Indications Bone metastases; Head and neck cancer; Lymphoma; Solid tumours
- Focus Adverse reactions
- 28 Sep 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 10 Jun 2017 Biomarkers information updated
- 28 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.